Hana Immunotherapeutics LLC - Mar 20, 2023 Form 3 Insider Report for Zura Bio Ltd (ZURA)

Role: 10%+ Owner
Signature: By: /s/ Chris Kim
Stock symbol: ZURA
Transactions as of: Mar 20, 2023
Transactions value $: $0
Form type: 3
Date filed: 4/4/2023, 09:55 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ZURA	Class A Ordinary Shares, par value $0.0001						5.4M	Mar 20, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Received on March 20, 2023, as consideration pursuant to that certain Business Combination Agreement originally dated June 16, 2022 ("Business Combination Agreement"), by and among Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"), JATT Acquisition Corp, a Cayman Islands exempted company ("JATT"), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT, JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT, and Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Business Combination"). The Reporting Person received the reported shares for its shares in Zura at the Exchange Ratio, as defined in the Business Combination Agreement, upon the closing of the Business Combination.
F2	The shares are held of record by Hana Immunotherapeutics LLC ("Hana"). Mr. Chris Kim is is the manager of Hana and as such has voting and investment power over the shares held by Hana. Mr. Kim disclaims beneficial ownership over all shares held by Hana over which he does not have a pecuniary interest.

Content

Received on March 20, 2023, as consideration pursuant to that certain Business Combination Agreement originally dated June 16, 2022 ("Business Combination Agreement"), by and among Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"), JATT Acquisition Corp, a Cayman Islands exempted company ("JATT"), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT, JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT, and Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Business Combination"). The Reporting Person received the reported shares for its shares in Zura at the Exchange Ratio, as defined in the Business Combination Agreement, upon the closing of the Business Combination.

The shares are held of record by Hana Immunotherapeutics LLC ("Hana"). Mr. Chris Kim is is the manager of Hana and as such has voting and investment power over the shares held by Hana. Mr. Kim disclaims beneficial ownership over all shares held by Hana over which he does not have a pecuniary interest.